ARK Diagnostics and Roche Diagnostics signed a letter of intent to negotiate an agreement that would grant Roche distribution and commercialization rights to ARK's anti-HIV drug monitoring products.
ARK's tests include immunoassay reagents for certain classes of anti-HIV drugs such as protease inhibitors and nonnucleoside reverse transcriptase inhibitors used to suppress viral replication. The immunoassay reagents are compatible with most automated clinical chemistry analyzers and measure a patient's blood level of anti-HIV drug, according to the companies.
“We are pleased to partner with Roche to leverage its distribution and marketing strengths to quickly get the anti-HIV drug monitoring products to market,” states Johnny Valdez, president of ARK. “Roche will be immediately selling and distributing our products worldwide.”